Our results suggest that treatment with a PRMT5 inhibitor in a syngeneic mouse erbB2/neu breast tumor model shows only a slight effect on tumor growth by itself, but significantly enhanced anti-erbB2 targeted antibody therapy. This evidence concerns the gene ERBB2 and breast neoplasm.